Irlanda - inglês - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - capecitabine - film-coated tablet - 150 milligram(s) - pyrimidine analogues; capecitabine

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - capecitabine - film-coated tablet - 500 milligram(s) - pyrimidine analogues; capecitabine

Israel - inglês - Ministry of Health

roche pharmaceuticals (israel) ltd - capecitabine 150 mg - film coated tablets - capecitabine - adjuvant colon cancer: xeloda is indicated for the adjuvant treatment of patients following surgery of stage iii (dukesע stage c) colon cancer. colorectal cancer: xeloda is indicated for the treatment of patients with advanced or metastatic colorectal cancer advanced gastric cancer: xeloda is indicated for first line treatment of advanced gastric cancer in combination with chemotherapy breast cancer combination therapy: xeloda in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. breast cancer monotherapy: xeloda is also indicated for the treatment of advanced or metastatic breast cancer after failure of standard therapy including a taxane unless therapy with a taxane is clinically contraindicated.

Israel - inglês - Ministry of Health

roche pharmaceuticals (israel) ltd - capecitabine 500 mg - film coated tablets - capecitabine - adjuvant colon cancer: xeloda is indicated for the adjuvant treatment of patients following surgery of stage iii (dukesע stage c) colon cancer. colorectal cancer: xeloda is indicated for the treatment of patients with advanced or metastatic colorectal cancer advanced gastric cancer: xeloda is indicated for first line treatment of advanced gastric cancer in combination with chemotherapy breast cancer combination therapy: xeloda in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. breast cancer monotherapy: xeloda is also indicated for the treatment of advanced or metastatic breast cancer after failure of standard therapy including a taxane unless therapy with a taxane is clinically contraindicated.

Cingapura - inglês - HSA (Health Sciences Authority)

lotus international pte. ltd. - capecitabine - tablet, film coated - 150.000 mg - capecitabine 150.000 mg

Cingapura - inglês - HSA (Health Sciences Authority)

lotus international pte. ltd. - capecitabine - tablet, film coated - 500 mg - capecitabine 500 mg

União Europeia - inglês - EMA (European Medicines Agency)

accord healthcare s.l.u. - capecitabine - colonic neoplasms; breast neoplasms; colorectal neoplasms; stomach neoplasms - antineoplastic agents - capecitabine accord is indicated for the adjuvant treatment of patients following surgery of stage-iii (dukes’ stage-c) colon cancer.capecitabine accord is indicated for the treatment of metastatic colorectal cancer.capecitabine accord is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.capecitabine accord in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline.capecitabine accord is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.

União Europeia - inglês - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - capecitabine - colorectal neoplasms - antineoplastic agents - capecitabine medac is indicated for the adjuvant treatment of patients following surgery of stage-iii (dukes’ stage-c) colon cancer.capecitabine medac is indicated for the treatment of metastatic colorectal cancer.capecitabine medac is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.capecitabine medac in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline.capecitabine medac is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.

União Europeia - inglês - EMA (European Medicines Agency)

teva pharma b.v. - capecitabine - colonic neoplasms; breast neoplasms; colorectal neoplasms; stomach neoplasms - antineoplastic agents - capecitabine teva is indicated for the adjuvant treatment of patients following surgery of stage iii (dukes’ stage c) colon cancer.capecitabine teva is indicated for the treatment of metastatic colorectal cancer.capecitabine teva is indicated for first‑line treatment of advanced gastric cancer in combination with a platinum‑based regimen.capecitabine teva in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline. capecitabine teva is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.

União Europeia - inglês - EMA (European Medicines Agency)

krka, d.d., novo mesto - capecitabine - colonic neoplasms; breast neoplasms; colorectal neoplasms; stomach neoplasms - antineoplastic agents - ecansya is indicated for the adjuvant treatment of patients following surgery of stage-iii (dukes’ stage-c) colon cancer.ecansya is indicated for the treatment of metastatic colorectal cancer.ecansya is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.ecansya in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline. ecansya is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.